Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of April 2026. The filing, dated April 29, 2026, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The company is headquartered in Geneva, Switzerland, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative operational data.
Material Changes
No material changes to financial results or operations are detailed within the text of this Form 6-K. The filing references the press release for specific updates but does not summarize comparative period data or financial variances.
Guidance, Outlook, and Risks
The filing explicitly states that the company's business faces significant risks and that results could materially differ from forward-looking statements. It directs investors to the Annual Report on Form 20-F for the year ended December 31, 2024 (filed May 15, 2025) for a comprehensive list of risk factors. The press release incorporated by reference is intended to provide the specific outlook or event details for this period.
Key Facts for Investor Verification
- Review the attached press release (Exhibit 99.1) for the specific announcement triggering this filing.
- Consult the Annual Report on Form 20-F for the year ended December 31, 2024, for detailed risk factors and historical financial context.
- Verify the company's current cash position and runway, as this filing does not disclose updated liquidity figures.
- Confirm the status of any clinical trials or regulatory milestones mentioned in the April 29, 2026 press release.